Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Female Breast Cancer Patients|Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer|HRD Positive Advanced Breast Cancer
Interventions: DRUG: Adebrelimab plus Fluzoparib
Sponsor: Zhejiang Cancer Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.